Precision Medicine in Oncology®

Hsp90 may be referred to as the 'guardian of the proteome,' since it regulates the correct structure and function of many of the important proteins encoded by our DNA.

Dr. Edith Perez, from the Mayo Clinic, Describes the Breast Cancer Translational Genomics Program

Before the oncology treatment paradigm can move from a one-size-fits-all model to true personalized medicine, the medical establishment must find a cost-effective way to identify biomarkers.

The long-sought aim of treating malignant disease by targeting particular molecular abnormalities is becoming a reality in an increasing number of clinical settings.

The USC Norris Comprehensive Cancer Center and Hospital has long enjoyed a national reputation as a leading resource for cancer research, treatment, prevention, and education.

Agents that target the c-MET pathway may prove to have significant benefit when combined with inhibitors of angiogenesis.

The keynote address at the ASCO Genitourinary Cancers Symposium highlighted a collaborative effort to develop a comprehensive molecular classification of prostate cancer.

Optical biomarkers derived from nondysplastic metaplastic cells can detect the presence of high-grade dysplasia and adenocarcinoma from Barrett's esophagus.

Dr. Neil Spector, from Duke Cancer Institute, Discusses the Systemic Nature of Cancer

This issue of Contemporary Oncology includes a focus on 2 challenging situations: management of metastatic TNBC and of advanced stage NSCLC.

The use of advanced gene analysis techniques in a small group of women with triple-negative metastatic breast cancer has revealed activity in two pathways found in most patients with this subtype.

As research progresses, optimal treatment of breast cancer will involve individualization of therapy to focus on specific targets driving each patient's cancer.

Dr. Charles Perou, from the UNC Lineberger Comprehensive Cancer Center, on Next Generation Sequencing Technology

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, on Targeted Therapies for Diffuse Large B-cell Lymphoma

Dr. Matthew Ellis, from Siteman Cancer Center, Describes Breast Cancer Heterogeneity

HER2 status in patients with breast cancer has emerged as a durable and effective marker for evaluating tumors and selecting therapies.

Researchers are reporting better survival rates in women with invasive EOC and germline mutations in the tumor suppressor genes BRCA1 and BRCA2 than in patients who are noncarriers.

Dr. Neil Spector, from the Duke Cancer Institute, Discusses the Complexities of Cancer

Dr. Kieron Dunleavy, from the National Cancer Institute, Discusses ABC DLBCL Research

The MET signaling network has emerged as an important target for cancer therapy, with a particularly significant role in controlling the cancer hallmarks of metastasis and angiogenesis.

Dr. Jenny Chang, from the Methodist Cancer Center, Discusses Combining HER2 Targeted Therapies

The Massachusetts General Hospital (MGH) Cancer Center comprises 23 fully integrated, multidisciplinary clinical programs, as well as an extensive array of support and educational services.

Jill M. Siegfried, PhD, is an investigator into the role of growth factors and hormones in the development and growth of lung cancer.

It is always difficult to distinguish what may legitimately be considered disease flare from the more likely scenario of the events simply representing the natural history of the malignancy.

The DDIs between Co-Rx medications and targeted OAD is associated with a significant decrease in effectiveness and increased toxicity.